The use of orally bioavailable small molecules BRAF inhibitors has gained significant attention in oncology after the success of FDA-approved drugs targeting the BRAF V600E mutation in melanoma, papillary thyroid cancer, BRAF mutated non–small cell lung cancer and hairy cell leukemia (48–51). The gene discussed is BRAF; the disease is lung cancer.